Hypofractionation in localised prostate cancer
Victoria Navarro Aznar,
Spain
PO-1402
Abstract
Hypofractionation in localised prostate cancer
Authors: Victoria Navarro Aznar1, Agustina Méndez Villamón1, Cristina García Aguilera1, José Miguel Ponce Ortega1, María Cerrolaza Pascual1, Alberto Lanuza Carnicer2, Julia Díaz Abad1, Cecilia Escuín Troncho1, Blanca García Gimeno1, David Villa Gazulla1
1Hospital Universitario Miguel Servet, Radiation Oncology, Zaragoza, Spain; 2Hospital Universitario Miguel Servet, Radiation oncology, Zaragoza, Spain
Show Affiliations
Hide Affiliations
Purpose or Objective
To analyse overall survival (OS); cancer-specific survival (CSS);
disease-free survival (DFS) and acute and chronic toxicity in patients with
localised prostate cancer treated with extracranial stereotactic radiotherapy
(SBRT).
Material and Methods
We retrospectively analysed 366 patients with localised prostate cancer
treated with SBRT between February 2014 and October 2021.
All received dietary recommendations and rectal preparation with enema
the night before the planning CT scan, which was performed with diuresis
control, immobilisation system with wedge under knees and abdominal compressor
with 3mm cuts.
Intensity modulated radiotherapy was applied using a Linear Electron
Accelerator with a photon beam energy of 6MV, administering 35Gy in 7 sessions
over the prostate volume with a margin of 3mm.
Weekly follow-up was carried out during the treatment and once it was
finished: at one month, 3 months, to continue with six-month follow-up.
Results
The median age was 72 years. 64.66% had received previous hormone
treatment. 38% were low risk, 56% intermediate risk and 6% high risk.
With a median follow-up of 39 months, DFS was 97.81% and CSS was 99.45%
with an OS of 90.22%.
The IPSS score increased a median of 2 points and normalised after 6
months to baseline values.
52% experienced acute genitourinary toxicity G1, 4% G2, and 1% G3. Acute
G1 gastrointestinal toxicity was experienced in 9% and G2 in 1%. After 6
months, G1 genitourinary toxicity was reported in 3%, G2 in 1%, G1
gastrointestinal toxicity in 1% and G2 in 1%. No toxicities ≥ grade 3 were
observed.
Conclusion
SBRT 35Gy is positioned as a safe treatment, with excellent disease
control, requiring longer-term follow-up.